LYEL Long Put Strategy
LYEL (Lyell Immunopharma, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
LYEL (Lyell Immunopharma, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $270.9M, a beta of -0.09 versus the broader market, a 52-week range of 8.632-45, average daily share volume of 128K, a public-listing history dating back to 2021, approximately 161 full-time employees. These structural characteristics shape how LYEL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of -0.09 indicates LYEL has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a long put on LYEL?
A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.
Current LYEL snapshot
As of June 30, 2026, spot at $13.53, ATM IV 384.10%, IV rank 89.23%, expected move 110.12%. The long put on LYEL below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this long put structure on LYEL specifically: LYEL IV at 384.10% is rich versus its 1-year range, which makes a premium-buying LYEL long put relatively expensive in absolute-cost terms, with a market-implied 1-standard-deviation move of approximately 110.12% (roughly $14.90 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated LYEL expiries trade a higher absolute premium for lower per-day decay. Position sizing on LYEL should anchor to the underlying notional of $13.53 per share and to the trader's directional view on LYEL stock.
LYEL long put setup
The LYEL long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With LYEL near $13.53, the first option leg uses a $14.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed LYEL chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 LYEL shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $14.00 | $2.50 |
LYEL long put risk and reward
- Net Premium / Debit
- -$250.00
- Max Profit (per contract)
- $1,149.00
- Max Loss (per contract)
- -$250.00
- Breakeven(s)
- $11.50
- Risk / Reward Ratio
- 4.596
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.
LYEL long put payoff curve
Modeled P&L at expiration across a range of underlying prices for the long put on LYEL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -99.9% | +$1,149.00 |
| $3.00 | -77.8% | +$849.95 |
| $5.99 | -55.7% | +$550.91 |
| $8.98 | -33.6% | +$251.86 |
| $11.97 | -11.5% | -$47.18 |
| $14.96 | +10.6% | -$250.00 |
| $17.95 | +32.7% | -$250.00 |
| $20.94 | +54.8% | -$250.00 |
| $23.93 | +76.9% | -$250.00 |
| $26.92 | +99.0% | -$250.00 |
When traders use long put on LYEL
Long puts on LYEL hedge an existing long LYEL stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying LYEL exposure being hedged.
LYEL thesis for this long put
The market-implied 1-standard-deviation range for LYEL extends from approximately $-1.37 on the downside to $28.43 on the upside. A LYEL long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long LYEL position with one put per 100 shares held. Current LYEL IV rank near 89.23% sits in the upper third of its 1-year distribution, which historically reverts; this raises the bar for premium-buying structures and lowers it for premium-selling structures on LYEL at 384.10%. As a Healthcare name, LYEL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to LYEL-specific events.
LYEL long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. LYEL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move LYEL alongside the broader basket even when LYEL-specific fundamentals are unchanged. Long-premium structures like a long put on LYEL are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current LYEL chain quotes before placing a trade.
Frequently asked questions
- What is a long put on LYEL?
- A long put on LYEL is the long put strategy applied to LYEL (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With LYEL stock trading near $13.53, the strikes shown on this page are snapped to the nearest listed LYEL chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are LYEL long put max profit and max loss calculated?
- Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the LYEL long put priced from the end-of-day chain at a 30-day expiry (ATM IV 384.10%), the computed maximum profit is $1,149.00 per contract and the computed maximum loss is -$250.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a LYEL long put?
- The breakeven for the LYEL long put priced on this page is roughly $11.50 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current LYEL market-implied 1-standard-deviation expected move is approximately 110.12%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long put on LYEL?
- Long puts on LYEL hedge an existing long LYEL stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying LYEL exposure being hedged.
- How does current LYEL implied volatility affect this long put?
- LYEL ATM IV is at 384.10% with IV rank near 89.23%, which is elevated relative to its 1-year range. Premium-selling structures (covered call, cash-secured put, iron condor) generally look more attractive when IV rank is high; premium-buying structures (long call, long put, debit spreads) are more expensive in that regime.